Ascendis Pharma (ASND) Financial Analysis & Valuation | Quarter Chart
Ascendis Pharma (ASND)
ASNDPrice: $263.7
Fair Value: 🔒
🔒score
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults wit... more
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medic... more
Description
Shares
| Market Cap | $16.38B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DK | CEO | Jan Moller Mikkelsen |
| IPO Date | 2015-01-28 | CAGR | 0.34% |
| Employees | 1,017 | Website | ascendispharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.31% | Total Yield | 0.31% |
ASND chart loading...
Fundamentals
Technicals
| Enterprise Value | $13.65B | P/E Ratio | -108.97 |
| Forward P/E | 27.96 | PEG Ratio | — |
| P/S Ratio | 17.23 | P/B Ratio | 30.55 |
| P/CF Ratio | 258.89 | P/FCF Ratio | 354.91 |
| EPS | $-2.42 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 135.29% | Gross Margin | 0.88% |
| Operating Margin | -0.01% | Profit Margin | 0.58% |
| ROE | -56.42% | ROA | 0.25% |
| ROCE | -0.01% | Current Ratio | 1 |
| Quick Ratio | 0.72 | Cash Ratio | 0.51 |
| Debt/Equity | 1.84 | Interest Coverage | -0.04 |
| Altman Z Score | 4.58 | Piotroski Score | 5 |